Trial reportEuropean journal of nuclear medicine and molecular imaging2020
Dosimetry and safety of
Trial report in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03454750 (Radiometabolic Therapy), which is not on this map. Cited by 36 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC): Efficacy and Toxicity Evaluation
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Dosimetry of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Pooled it
- Joint EANM/SNMMI procedure guideline for the use ofEuropean journal of nuclear medicine and molecular imaging · 2023Guideline
- Pooled it
- Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2020Pooled it
- Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study.European journal of nuclear medicine and molecular imaging · 2026Trial
- The Impact of Monosodium Glutamate onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- 177 Lu-PSMA for prostate cancer: progress, challenges and future perspectives.Asian journal of andrology · 2026Review
- PSMA-1-DOTA Potentially for Effective Targeted Radioligand Therapy of Prostate Cancer.Molecular imaging and biology · 2025Article
- Preliminary clinical study of p-iodo benzoyl moiety-modified PSMA inhibitors and prospective comparison with 68Ga-PSMA-11.Scientific reports · 2025Article
- Current Status and Future Perspectives of Nuclear Medicine in Prostate Cancer from Imaging to Therapy: A Comprehensive Review.Biomedicines · 2025Review
- Long-Term Safety and Survival Outcomes of [Cancers · 2025Article
- Validation of dosimetry programs (Olinda & IDAC) for evaluation of absorbed dose inEJNMMI physics · 2024Article
- Searching for Protein Off-Targets of Prostate-Specific Membrane Antigen-Targeting Radioligands in the Salivary Glands.Cancer biotherapy & radiopharmaceuticals · 2024Article
- A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?EJNMMI physics · 2024Review
- Organ and tumor dosimetry including method simplification for [EJNMMI physics · 2024Article
- Lutetium-177-Prostate-Specific Membrane Antigen Radioligand Therapy: What Is the Value of Post-Therapeutic Imaging?Biomedicines · 2024Review
- Actinium-225 targeted alpha particle therapy for prostate cancer.Theranostics · 2024Review
- PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?Theranostics · 2024Article
- Performance study of a 360° CZT camera for monitoringEJNMMI physics · 2023Article
- Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRadioligand therapy (RLT) with PATIENTS AND
methodsA prospective single-arm, open label phase II study on mCRPC was activated at our institute in April 2017. Patients with histologically confirmed advanced mCRPC previously treated with standard life-prolonging agents were enrolled. Folic polyglutamate tablets were orally administered as parotid gland protectors and 500 mL of a 10% mannitol solution was intravenously infused to reduce kidney uptake before the injection of 3.7-5.5 GBq of
resultsForty-three eligible patients were evaluated for toxicity and initial response. Dosimetry was carried out in 13 patients. Two (4.8%) patients had G3 and 8 (19.5%) had G2 hematological toxicity. Only 3 (6.9%) patients had mild G1 salivary gland toxicity and 8 (19.5%) had G1 renal toxicity. A decrease of ≥ 30% in prostate-specific antigen (PSA) was achieved after the first cycle in 17 (40.5%) patients, of whom 13 had a PSA decline of >50% after the second cycle. The median adsorbed doses were 0.65 mGy/MBq (range 0.33-2.63) for parotid glands, 0.42 mGy/MBq (0.14-0.81) for kidneys, 0.036 mGy/MBq (0.023-0.067) for red marrow, and 0.038 mGy/MBq (0.018-0.135) for the whole body.
conclusionIn advanced, heavily pre-treated mCRPC patients, 3.7 GBq/cycle of CLINICAL
trial registrationEU Clinical Trials Register No.: 2016-002732-32; NCT03454750. Collection and assembly of data: April 2017 and February 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.